SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Amazon.com, Inc. is a multinational technology company, which engages in the provision of online retail shopping services. It operates through the following segments: North America, International, and Amazon Web Services (AWS). The North America segment offers retail sale of consumer products, including from sellers, advertising, and subscriptions services through North America-focused online and physical stores. The International segment focuses on retail sale of consumer products, including sellers, advertising, and subscription services through internationally focused online stores. The AWS segment is composed of global sales of computers, storage, databases, and other services for start-ups, enterprises, government agencies, and academic institutions. The company was founded by Jeffrey P. Bezos in July 1994 and is headquartered in Seattle, WA.

Amazon.com Inc.

Amazon.com Inc

Amazons sharp move is drawing attention after Morgan Stanley named it a top pick, citing accelerating AWS growth and AI opportunities; traders are also pointing to Amazons Trainium software announcement as a potential boost to cloud-chip adoption. The reaction is broadly bullish, though some remain cautious about heavy AI capital spending and whether the gains will hold.

Xeris Biopharma Holdings, Inc. is a biopharmaceutical company, which engages in developing and commercializing products across a range of therapies. Its products include Gvoke, Keveyis, and Recorlev. Gvoke is a ready-to-use liquid glucagon for the treatment of severe hypoglycemia. Keveyis is the therapy approved in the United States to treat hyperkalemic, hypokalemic, and related variants of primary periodic paralysis (PPP). Recorlev is a cortisol synthesis inhibitor approved for the treatment of endogenous hypercortisolemia in adult patients with Cushing’s syndrome. The company was founded by Steven Prestrelski in 2005 and is headquartered in Chicago, IL.

Xeris Biopharma Holdings Inc

Reports of Lundbecks interest in acquiring Xeris have fueled heavy-volume trading and takeover speculation, though the company has said it is not for sale and no deal is confirmed. Traders are split between expecting further buyer interest and viewing the chatter as unsubstantiated, while some point to Recorlev growth and XP-8121s pipeline potential as standalone reasons for optimism.

Disc Medicine, Inc. is a clinical-stage biopharmaceutical company, which engages in the discovery, development, and commercialization of treatments for hematologic diseases. It assembles a portfolio of clinical and preclinical product candidates that aim to modify fundamental biological pathways associated with the formation and function of red blood cells, specifically heme biosynthesis and iron homeostasis. The company was founded in October 2017 and is headquartered in Watertown, MA.

Disc Medicine Inc

Disc Medicine shares surged after bitopertin met all primary and secondary endpoints in the Phase 3 APOLLO trial for erythropoietic protoporphyria, supporting a planned FDA resubmission. Traders are debating whether the move can continue, with some citing short-squeeze potential and others warning of profit-taking, safety concerns around dizziness, and the fact that FDA approval is still pending.

Celsius Holdings, Inc. engages in the development, marketing, sale, and distribution of functional drinks and liquid supplements. It also offers post-workout functional energy drinks and protein bars. The company was founded in April 2004 and is headquartered in Boca Raton, FL.

Celsius Holdings Inc

A cluster of reported open-market purchases by Celsius executives and directors is fueling bullish interest, with traders reading the buying as a sign of confidence and some speculating about a potential Pepsi bid or short covering. Skeptics counter that insider buying does not resolve concerns about weakness in the core Celsius brand, growth, and management execution.

Vicor Corp. engages in the design, development, manufacture, and marketing of modular power components. The firm provides complete power systems based upon a portfolio of patented technologies. Its products include AC-DC converters, power systems, and accessories. The company was founded by Patrizio Vinciarelli in 1981 and is headquartered in Andover, MA.

Vicor Corp.

Anticipation of Vicors Q3 earnings is driving discussion after the company raised its sequential growth outlook twice, with traders pointing to higher royalties from its Vertical Power Delivery licensing. Bulls expect the stronger outlook to show up in results, while others are wary of the sharp pullback and volatility despite the guidance increases.

Ocular Therapeutix, Inc. is a biopharmaceutical company, which engages in the development and commercialization of therapies for diseases and conditions of the eye. Its product pipeline includes Dextenza, OTX-TP, and OTX-TIC. The company was founded by Amarpreet S. Sawhney and Farhad Khosravi on September 12, 2006 and is headquartered in Bedford, MA.

Ocular Therapeutix Inc

Ocular Therapeutix shares are under pressure as EyePoints failed wet-AMD trial has heightened doubts about TKI-based treatments, prompting traders to question whether those concerns could extend to Oculars AXPAXLI program. Some investors view the selloff as spillover from a competitors results, while others cite clinical uncertainty and the departure of Oculars chief strategy officer as additional concerns.

Alpha Tau Medical Ltd. is a clinical-stage oncology therapeutics company, which focuses on the research, development, and commercialization of diffusing alpha-emitters radiation therapy for the treatment of cancer. The firm is involved in the clinical trials at cancer centers with indications that include skin cancer, oral cavity cancer, breast cancer, and pancreatic cancer. The company was founded by Uzi Sofer, Yona Keisari, and Itzhak Kelson in November 2015 and is headquartered in Jerusalem, Israel.

Alpha Tau Medical Ltd

ALPHA TAU MEDICAL LTD

The FDA-cleared expansion of Alpha Taus REGAIN trial in recurrent glioblastoma is a key focus, alongside planned trial data at SNO 2026. Traders are optimistic about early local-control results, while some note that they come from a small initial cohort; the completed enrollment of the pancreatic IMPACT study is another pipeline catalyst discussed.

Cleveland-Cliffs, Inc. is a flat-rolled steel company, which engages in provision of iron ore pellets to the North American steel industry. It focuses on the production of metallic and coke, iron making, steelmaking, rolling and finishing, and downstream tubular components, stamping, and tooling. It operates through the Steelmaking and Other Businesses segments. The company was founded in 1847 and is headquartered in Cleveland, OH.

Cleveland-Cliffs Inc

A stronger-than-guided Q3 report and an upbeat 2027 EBITDA outlook are driving CLFs rally. Bulls see improving steel prices and earnings potential, while skeptics warn that debt and the reliance on favorable price forecasts could limit the recovery; traders are also debating whether the move will hold or fade as a sell-the-news rally.

Cerebras Systems, Inc. engages in the designing and provision of processors for artificial intelligence (AI) training and inference. Its products include inference, Wafer Scale Engine, AI supercomputers, AI model services, cloud, systems, and processors. The company was founded by Sean Lie, Andrew D. Feldman, Gary Lauterbach, Michael James, and Jean Philippe Fricker in 2015 and is headquartered in Sunnyvale, CA.

Cerebras Systems Inc - Ordinary Shares - Class A

Cerebras Systems Inc

Cerebras steep post-IPO decline dominates discussion, with traders pointing to insider selling and upcoming share unlocks alongside concerns about valuation, scaling and reliance on OpenAI amid weakness across AI stocks. Some see the selloff as an oversold buying opportunity and are averaging in, while others expect further downside.

Invesco QQQ Trust Series 1 - Invesco QQQ Trust Series 1

QQQ rebounded as technology and AI stocks recovered from a sharp selloff, with traders debating whether the move marks a durable recovery or a low-volume bull trap. Upcoming megacap earnings and AI spending plans are a key focus for the tech-heavy index.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Strengthen Your Portfolio With These Cybersecurity ETFs

AI safety concerns and rising cyber threats are fueling demand for cybersecurity. Here are ETFs positioned to benefit from growing security needs.

Time to Boost Cybersecurity ETF Exposure as AI Safety Concerns Rise

AI safety concerns are rising, but that could create another tailwind for cybersecurity. Here are ETFs positioned to benefit from growing security needs.

Cybersecurity Demand Fuels CrowdStrike's Earnings Beat: ETFs in Focus

CrowdStrike's earnings beat highlights strong cybersecurity demand. Discover ETFs positioned to benefit from CRWD's growth and the broader sector's momentum.

A Guide to Investing in Cybersecurity ETFs

AI is transforming cybersecurity-and cybercrime. Here are cybersecurity ETFs positioned to capitalize on rising demand.

5 ETF Areas Trading at a 52-Week High

AI momentum, defensive investing and elevated energy prices are pushing several ETF areas to fresh 52-week highs in 2026.

Hack-Proof Your Portfolio: The Bull Case for Cybersecurity ETFs

As AI investments surge, AI-driven cyberattacks are rising in parallel, boosting the case for cybersecurity ETFs.

Growing AI Risks & Defense Demand Boost Cybersecurity ETFs' Appeal

As AI adoption and cyberwarfare accelerate, cybersecurity ETFs may offer a compelling investment opportunity.

DDOG Stock Races Toward Best Week Ever After $1B Revenue Milestone — Stifel Sees 61% More Upside Ahead

Equity

Datadog is also on track to be the top gainer this week on the Nasdaq 100 and the second-best performer on the S&P 500. 


Are Tech ETFs New Safe Haven Amid Iran War?

Iran war volatility lifts oil and rattles stocks. But tech ETFs, powered by AI, cloud and cybersecurity demand, are emerging as surprising defensive plays.

Cyberwarfare Threat Rises: Time to Boost Cybersecurity ETF Exposure?

From AI expansion to cyberwarfare, cybersecurity ETFs may offer a compelling investment opportunity.

WisdomTree Trust - WisdomTree Cybersecurity Fund

Bearish Sentiment

<ul class="summary-bullets"><li>Datadog’s customer usage is growing at the fastest rate since early 2022.&nbsp;</li><li>Jefferies, Stifel, and Evercore ISI raised their price targets after Q1 earnings.&nbsp;</li><li>Jefferies kept a Buy rating, citing the strongest customer usage growth since early 2022.&nbsp;</li></ul>Datadog,&nbsp;Inc.’s stock (DDOG) is&nbsp;on track to notch its best weekly performance on record&nbsp;as the cloud company delivered a breakout first-quarter (Q1) earnings that ignited investor enthusiasm and&nbsp;underscored its key role in the artificial intelligence infrastructure boom.The stock is also set to be the biggest winner this week on the Nasdaq-100 and the second-best performer on the S&amp;P 500.<h2 class="st-heading-2">Wall Street Backs DDOG’s Strengthening Growth Trends</h2>Jefferies, Stifel and Evercore ISI all raised their price targets on Datadog after what analysts broadly described as a solid “beat and raise” quarter. The firms cited stronger-than-anticipated demand, improving guidance and continued momentum in both core and AI-related products.Jefferies raised its price target&nbsp;on DDOG to $210 from $170 and kept a ‘Buy’ rating, according to TheFly. The firm said customer usage grew at its fastest rate since early 2022, showing strong momentum in its main platform services.&nbsp;Stifel made a more aggressive revision, raising its target to $305 from $160 and also reiterating a ‘Buy’ rating. The firm emphasized that revenue growth continued to pick up sequentially. The new price target implies a 61% upside&nbsp;from the stock’s closing price on Thursday.&nbsp;Evercore ISI also raised its price target to $225 from $175, maintaining an Outperform rating. The firm said the company’s quarterly results and forward guidance helped ease concerns that growth might slow later in the year.<a href="https://stocktwits.com/symbol/DDOG">Datadog stock</a> traded over 1% lower overnight late Thursday, after surging over 31% in the regular session.&nbsp;<h2 class="st-heading-2">DDOG’s&nbsp;Strong Growth Across Core Metrics</h2>In Q1, Datadog posted revenue of $1.006 billion, reaching its first-ever billion-dollar mark and beating analyst expectations of $959.9 million. Adjusted earnings per share came in at $0.60, well above the $0.51 Street forecast, according to Fiscal AI data.&nbsp;&nbsp;The company continued to deepen its enterprise base, growing to roughly 4,550 customers generating more than $100,000 in annual recurring revenue, up from about 3,770 a year earlier.&nbsp;<figure class="image"><img src="https://news.stocktwits-cdn.com/fiscal_ai_chart_export_5_jpg_b31393eadc.webp" alt="DataDog Sees Stellar Growth In Customer Base &amp; Revenue" width="2160" height="2160"><figcaption>DataDog Sees Stellar Growth In Customer Base &amp; Revenue</figcaption></figure>Looking ahead, the company sees Q2 revenue between $1.07 billion and $1.08 billion and EPS between $0.57 and $0.59,&nbsp;compared with the Street estimates of $1.06 billion and $0.58, respectively.&nbsp;<h2 class="st-heading-2">What Are DDOG Retail Traders Saying?&nbsp;</h2>On Stocktwits, retail sentiment around the stock remained in ‘extremely bullish’ territory with 1,377% surge in message volume over 24 hours.&nbsp;<figure class="image"><img src="https://news.stocktwits-cdn.com/Screenshot_2026_05_07_235301_png_1dc0b0ef62.webp" alt="DDOG’s Sentiment Meter and Message Volume as of 23:40 p.m. ET on May. 7, 2026 | Source: Stocktwits" width="927" height="101"><figcaption>DDOG’s Sentiment Meter and Message Volume as of 23:40 p.m. ET on May. 7, 2026 | Source: Stocktwits</figcaption></figure>A user&nbsp;<a href="https://stocktwits.com/informal/message/652690993">said</a>, “<a href="https://stocktwits.com/symbol/DDOG">$DDOG</a> earnings just proved high-value SaaS isn’t dying because of AI, it’s accelerating.”Another user said, “damn, I missed this one.&nbsp; Crushing growth with expanding margins.”<stembedurl>https://stocktwits.com/asjos77/message/652686899</stembedurl>DDOG stock has gained over 38% year-to-date.Also See:&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/ttd-stock-sinks-overnight-on-weak-outlook-but-ceo-feels-best-days-are-ahead/cZX2P0EReQv">TTD Stock Sinks Overnight On Weak Outlook, But CEO Feels ‘Best Days Are Ahead’</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

In this photo illustration, a smartphone displays the logo of Datadog, Inc.

Datadog is also on track to be the top gainer this week on the Nasdaq 100 and the second-best performer on the S&P 500. 

First Trust Exchange-Traded Fund III - First Trust NASDAQ Cybersecurity ETF

Datadog Inc

$SPCX

$NFLX

$TSLA

$META

Which earnings release are you most looking forward to this week: $SPCX, $NFLX, $TSLA, or $META? Drop a comment for others.

Current Price	$44.94
Prev Close	$43.92
Open	$44.59
Dividend Yield	N/A
50-Day Moving Average	$43.27
Beta	N/A
Avg. Volume	88,465.72
PE Ratio	N/A

52-Week High	$50.38
52-Week Low	$22.49
Market Capitalization	N/A
EPS (Annual)	N/A
Price to Book	N/A
Revenue Per Employee	N/A

Feed

News

Sentiment

Fundamentals

Info

WCBR Fundamentals